乙酰唑胺在急性心衰容量超负荷患者的利钠反应
基于ADVOR试验中462例患者的分析,乙酰唑胺独立预测尿钠浓度升高16 mmol/L(19%)及总利钠量增加115 mmol(32%);利钠反应越强,容量超负荷缓解越快越完全,住院更短,且每10 mmol/L尿钠升高与全因死亡或心衰再入院风险降低独立相关(HR 0.92)。
要点
- 乙酰唑胺使尿钠浓度提高16 mmol/L、总利钠量增加115 mmol。
- 利钠反应越强,容量超负荷缓解越快越完全,住院时间更短。
- 尿钠每升高10 mmol/L,全因死亡或心衰再入院风险HR 0.92。
核心结论
- 在急性失代偿性心衰中,利钠增加与乙酰唑胺成功减容密切相关。
- 尿钠浓度可能是未来试验中评价有效减容的有吸引力的指标。
研究设计与样本
- ADVOR试验的事后分析,纳入462/519例(89%)有完整尿量和尿钠浓度数据的患者。
主要发现
- 随机后2天内平均尿钠浓度为92 ± 25 mmol/L,总利钠量为425 ± 234 mmol。
- 乙酰唑胺分配独立预测利钠:尿钠浓度升高16 mmol/L(19%),总利钠量增加115 mmol(32%)。
- 较高的收缩压、较好的肾功能、较高的血钠水平和男性也独立预测更高的尿钠浓度和更大的总利钠量。
- 利钠反应越强与容量超负荷体征更快更完全缓解相关,在评估第一个早晨即显著(P = 0.022)。
- 乙酰唑胺分配与尿钠对减容的效应存在显著交互作用(P = 0.007),利钠越强减容越好则住院更短(P < 0.001)。
关键数值与推荐
- 多变量调整后,尿钠浓度每增加10 mmol/L与全因死亡或心衰再入院风险降低独立相关(HR: 0.92; 95% CI: 0.85-0.99)。
临床怎么用
- 在急性心衰容量超负荷患者中,可关注乙酰唑胺治疗后的尿钠反应以评估减容效果。
- 尿钠浓度可作为评价减容有效性的潜在指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acetazolamide facilitates decongestion in acute decompensated heart failure (ADHF). OBJECTIVES: This study sought to investigate the effect of acetazolamide on natriuresis in ADHF and its relationship with outcomes. METHODS: Patients from the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial with complete data on urine output and urine sodium concentration (UNa) were analyzed. Predictors of natriuresis and its relationship with the main trial endpoints were evaluated. RESULTS: This analysis included 462 of 519 patients (89%) from the ADVOR trial. During 2 days after randomization, UNa was 92 ± 25 mmol/L on average, and total natriuresis was 425 ± 234 mmol. Allocation to acetazolamide strongly and independently predicted natriuresis with a 16 mmol/L (19%) increase in UNa and 115 mmol (32%) greater total natriuresis. Higher systolic blood pressure, better renal function, higher serum sodium levels, and male sex also independently predicted both a higher UNa and greater total natriuresis. A stronger natriuretic response was associated with faster and more complete relief of signs of volume overload, and this effect was already significant on the first morning of assessment (P = 0.022). A significant interaction was observed between the effect of allocation to acetazolamide and UNa on decongestion (P = 0.007). Stronger natriuresis with better decongestion translated into a shorter hospital stay (P < 0.001). After multivariable adjustments, every 10 mmol/L UNa increase was independently associated with a lower risk of all-cause death or heart failure readmission (HR: 0.92; 95% CI: 0.85-0.99). CONCLUSIONS: Increased natriuresis is strongly related to successful decongestion with acetazolamide in ADHF. UNa may be an attractive measure of effective decongestion for future trials. (Acetazolamide in Decompensated Heart Failure with Volume Overload [ADVOR]; NCT03505788).
引用
- Verbrugge, Martens, Dauw, et al. Natriuretic Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload. J Am Coll Cardiol. 2023. PMID: 37197845. doi:10.1016/j.jacc.2023.03.400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。